Patent · US Active

Treatment for migraine

US11471434B2 · kind B2 · utility

1Cited by

1References

20Claims

0Family size

Assignee

INTRABIO LTD. · GB

Inventors

Michael Strupp · Durmersheim, DE
Mallory Factor · London, GB

Key dates

Filing date	Jun 25, 2018
Grant date	Oct 18, 2022
Priority date	—
Expiry date	Oct 12, 2038

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P25/06
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

A first aspect of the invention relates to leucine, acetyl-leucine, or a pharmaceutically acceptable salt thereof, for use in treating or preventing a migraine, or one or more symptoms associated therewith. A second aspect of the invention relates to a method of treating or preventing a migraine, or one or more symptoms associated therewith, in a subject, said method comprising administering to the subject a therapeutically or prophylactically effective amount of leucine, acetyl-leucine, or a pharmaceutically acceptable salt thereof.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.